A detailed history of Virtu Financial LLC transactions in Chimerix Inc stock. As of the latest transaction made, Virtu Financial LLC holds 13,609 shares of CMRX stock, worth $13,200. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13,609
Holding current value
$13,200
% of portfolio
0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$0.87 - $1.05 $11,839 - $14,289
13,609 New
13,609 $12,000
Q4 2023

Feb 26, 2024

BUY
$0.9 - $1.06 $5,387 - $6,345
5,986 Added 25.59%
29,376 $28,000
Q3 2023

Nov 14, 2023

BUY
$0.94 - $1.23 $21,986 - $28,769
23,390 New
23,390 $22,000
Q4 2022

Feb 15, 2023

SELL
$1.67 - $2.35 $47,853 - $67,339
-28,655 Reduced 59.63%
19,400 $36,000
Q3 2022

Nov 07, 2022

SELL
$1.81 - $2.76 $24,286 - $37,033
-13,418 Reduced 21.83%
48,055 $93,000
Q2 2022

Aug 09, 2022

BUY
$1.34 - $5.34 $64,346 - $256,426
48,020 Added 356.95%
61,473 $128,000
Q1 2022

May 17, 2022

BUY
$4.58 - $6.8 $11,665 - $17,319
2,547 Added 23.35%
13,453 $62,000
Q4 2021

Feb 17, 2022

BUY
$5.23 - $7.18 $3,477 - $4,774
665 Added 6.49%
10,906 $70,000
Q3 2021

Nov 12, 2021

BUY
$5.94 - $8.75 $60,831 - $89,608
10,241 New
10,241 $63,000
Q3 2020

Dec 11, 2020

SELL
$2.3 - $3.72 $41,264 - $66,740
-17,941 Closed
0 $0
Q2 2020

Aug 07, 2020

SELL
$1.33 - $3.63 $6,547 - $17,870
-4,923 Reduced 21.53%
17,941 $56,000
Q4 2019

Feb 04, 2020

BUY
$1.3 - $2.72 $29,723 - $62,190
22,864 New
22,864 $46,000
Q2 2019

Aug 13, 2019

SELL
$2.05 - $4.32 $21,367 - $45,027
-10,423 Closed
0 $0
Q1 2019

Apr 12, 2019

BUY
$1.79 - $3.12 $18,657 - $32,519
10,423 New
10,423 $22,000
Q4 2017

Feb 09, 2018

SELL
$4.32 - $5.52 $57,144 - $73,018
-13,228 Closed
0 $0
Q3 2017

Nov 15, 2017

BUY
$4.35 - $5.25 $57,541 - $69,447
13,228
13,228 $0

Others Institutions Holding CMRX

About CHIMERIX INC


  • Ticker CMRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,622,896
  • Market Cap $85M
  • Description
  • Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs i...
More about CMRX
Track This Portfolio

Track Virtu Financial LLC Portfolio

Follow Virtu Financial LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtu Financial LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtu Financial LLC with notifications on news.